The cannabis plant is home to over 200 cannabinoids and terpenes that have potential health benefits. Following the wild success of delta 8 THC as a legal alternative to the more controlled availability of delta 9 THC, the cannabis industry has sought other less-known cannabinoids to compete in the diverse cannabis marketplace. One of the newest, semi-synthetic cannabinoids called hexahydrocannabinol, usually shortened to HHC.

Hexahydrocannabinol (HHC) is a cannabinoid that was first discovered in the mid-1940s. In 1944, the American chemist Roger Adams created HHC when he added hydrogen molecules to Delta-9 THC. This process is known as "hydrogenation." HHC is found in limited quantities in the hemp plant. Although HHC is a naturally occurring compound, it is hard to obtain sufficient amounts to make products. But by certain production processes, companies can convert CBD into HHC to make a wide variety of products.

While HHC has been around for years, it has not been often discussed by cannabis users until recently.. HHC is a minor cannabinoid; it occurs naturally in cannabis, but in amounts too small to make extraction cost-effective - this means that for companies to sell this cannabinoid, they’re going to need to make it in a lab. HHC does, however, have one major legal advantage over delta 8 and delta 10: it isn’t THC.

So how is HHC made?

As mentioned above, Roger Adams is the first person to discover HHC using the process known as ‘hydrogenation’. There are a couple of different methodologies to hydrogenate delta-8 into HHC, but Hydrogenation is simply treating a compound with hydrogen, which causes a chemical reaction between hydrogen and another compound or element, usually in the presence of a catalyst such as nickel, palladium, or platinum. This is done in order to reduce or saturate organic compounds.

Adams originally applied this technique to THC derived from marijuana plants, but since the 2018 Farm Bill came into effect, legalizing cannabis crops with less than 0.3% delta-9 THC, more manufacturers are applying the hydrogenation of cannabinoids to CBD to produce HHC.

When it comes to HHC specifically, Hydrogenation modifies the structure of delta 9 THC by replacing a double bond with two hydrogen atoms, which changes its molecular weight and makes it more stable. According to chemist Mark Scialdone;

“A major benefit to hydrogenation is that it offers stability at the molecular level, assisting with both shelf life, and resistance to heat.”

It should be said, though, that the acronym “HHC'' is also used in scientific literature to refer to dangerous synthetic substances like 9-Nor-9β-hydroxyhexahydrocannabinol and 11-Nor-9β-hydroxyhexahydrocannabinol. All those Greek letters and super-long hyphenated chemical names are surefire signs that these forms of HHC are synthetic.

What Are The Effects Of HHC?

First, it’s important to note the different types of HHC that are available on the market. There are at least 10 types of HHC:

1. HHC — Hexahydrocannabinol (CAS# 6692-85-9)
2. 7-OH-HHC — 7-hydroxyhexahydrocannabinol (CAS 64663-39-4)
3. 8-OH-iso-HHC — 8-hydroxy-iso-hexahydrocannabinol (No CAS#)
4. 9α-OH-HHC — 9α-hydroxyhexahydrocannabinol (CAS# 52171-85-4)
5. 7-9α-OH-HHC — 7-oxo-9α-hydroxyhexahydrocannabinol (No CAS#)
6. 10α-OH-HHC — 10α-hydroxyhexahydrocannabinol (No CAS#)
7. 10α-ROH-HHC — 10aR-hydroxyhexahydrocannabinol (No CAS#)
8. HU211 — 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol (CAS 112924-45-5)
9. HU243 — 11-Hydroxy-3-(1′,1′-dimethylheptyl)hexahydrocannabinol (CAS 140835-14-9)
10. HDHHC — 3-Dimethylheptyl-11-hydroxyhexahydrocannabinol (CAS 140835-18-3)

HHC has very similar effects to delta-9 THC—it's a psychotropic compound that produces feelings of euphoria, changes in perception, altered cognition, as well as other potential properties. When it takes on other forms, it becomes slightly more complicated. Many users report the effects of HHC are similar to that of delta 8 THC in terms of being more heavily weighted towards relaxation than stimulation. HHC is more potent than delta 8 but slightly less potent than delta 9 THC.

We've seen a sudden ride of THC isomers—variants of the notorious delta-9 THC molecule, as people look for a legal means to experience the intoxicating effects of marijuana. Popular THC cannabinoid analog isomers include delta-8 THC and delta-10 THC derived from hemp crops. Although HHC isn’t technically a THC, it does produce similar effects—if you use enough of it. When it’s produced in the lab, an HHC batch is a mix of active and inactive HHC molecules. The active HHC binds well with your body’s cannabinoid receptors; the others don’t.

A study published in 2010 found that HHC’s effects lasted a long time in rats. Overall, apart from the limited research outlined in this section, there is nothing else to link HHC with the benefits claimed by manufacturers. Certainly, there are no studies on humans that provide any insight.

Is HHC Legal?

Although HHC is not the same as THC, it is potentially illegal if deemed synthetic. The FDA’s Interim Final Rule (IFR) states that synthetic cannabinoids in hemp are illegal, while naturally-occurring ones are permitted. It is true that HHC occurs naturally in hemp and cannabis but only in tiny amounts. HHC manufacturers make it in a lab via a chemical process designed to create more of it.

With the rise of delta 8, hexahydrocannabinol was recognized as yet another form of “legal THC” capable of being sold to the masses. No matter how much marketing material you read, however, delta 8 and HHC will never be equitable. One is a synthetically derived cannabinoid while the other is a natural substance.

We wouldn’t be surprised if HHC starts getting attention from the DEA, as we suspect that considering the need to synthetically create it - HHC falls under the Federal Analogue Act, which automatically classifies analogs of Schedule 1 drugs as Schedule 1 drugs themselves. If the DEA agrees, HHC could have a very short market span.

Is HHC Safe?

As it stands, HHC is rarer and more difficult to derive than delta 8, the HHC market is smaller and less competitive, resulting in comparatively inferior products. Because hexahydrocannabinol (HHC) is still very new, there aren't very many studies available that investigate its potential effects and safety - which is enough to tell us that as it stands, it is not particularly safe.

With the limited research on HHC, we highly suggest that you stick to the better known cannabinoids with ample research surrounding it like CBDV which we have done extensive research into and offer safe, legal products containing this cannabinoid.

HHC seems to be following a very similar and dangerous route to THCO, another synthetic cannabinoid taking the industry by storm. We can only hope that the search for something stronger and different does not take priority over the search for something more beneficial and well-researched.

‍

The Entourage Effect is a concept you may have come across when researching CBD products. In fact, one of the reasons why many people opt for full-spectrum CBD instead of pure CBD is because of the entourage effect.

Understanding the entourage effect will help you understand how CBD affects your body. This will enable you to choose CBD products that affect your body the way you desire.

If you’ve shopped for CBD products, you’ll have noticed that they fall into three main categories:

1) CBD isolate, which is pure CBD.

2) Full-spectrum CBD, which contains high amounts of CBD as well as small amounts of the other cannabinoids and terpenes found in the plant, as well as flavonoids and terpenes.

3) Broad-spectrum CBD, which is full-spectrum CBD with some components removed, usually THC and CBD.

The type of CBD you choose depends on your needs. Many people opt for CBD isolate if they only want pure CBD. But what’s the benefit of full-spectrum CBD and broad-spectrum CBD? Why does it matter whether there are other cannabinoids in the product?

In essence, the magic of full-spectrum CBD and THC is in the entourage effect.

What is the Entourage Effect of CBD and THC?

The entourage effect is the theory that all compounds in the cannabis plant and hemp plants are more beneficial when taken together.

The Cannabis plant and hemp plants contain dozens of cannabinoids—perhaps as many as 120. The most well-known cannabinoids and terpenes are CBD and tetrahydrocannabinol, or THC. Every cannabinoid seems to work differently, and research suggests each one has a different effect on the body. Cannabinoids affect various parts of our body, from our skin and digestive system to our brain and heart.

In addition to cannabinoids, there are flavonoids, which affect the flavor and color of the bud, and terpenes, which affect the bud’s aroma and may have beneficial health entourage effects.

The entourage effect is the idea that cannabinoids and terpenes work better together. In other words, when CBD and THC are in the presence of other cannabinoids, their effect is more potent and more beneficial than when you take each cannabinoid individually. It is also believed that terpenes and flavonoids also add to the entourage effect.

One example of the power of the entourage effect is how CBD tames the effect of THC. THC, which gets you high, can have some side effects. For example, some people find that it makes them anxious. A 2019 study shows that CBD seems to offset some of these side effects, thus “balancing” the not-so-great effects of cannabis and THC without reducing its benefits and entourage effect.

Another example of the entourage effect in action is Sativex. Sativex is an FDA-approved medication, often used to treat pain in people with multiple sclerosis. Sativex combines CBD and THC, as researchers found that they soothe pain better when they’re used together.

A 2011 study also suggests that, when terpenes and cannabinoids are taken together, they could have a more potent effect in treating:

• Pain and inflammation
• Anxiety and stress
• Epilepsy and other seizure conditions
• Cancer
• Fungal infections

Further research conducted in 2018 found that certain flavonoids and terpenes could have beneficial properties, such as anti-inflammatory and neuroprotective effects. The authors suggested that these compounds, when combined with cannabinoids and terpenes, could have a more potent and beneficial effect.

With all this in mind, it’s no wonder why so many people opt for full-spectrum CBD and THC. However, it’s important to remember that high doses of THC can show up in a drug test—so be cautious when opting for high-THC products.

What do Other Cannabinoids Do?

You’ve heard of THC and CBD, but what are the other cannabinoids called? And more importantly, what do they do?

Tetrahydrocannabinol (THC)

Along with CBD, THC is one of the most well-known and well-studied cannabinoids. THC is the part of cannabis that gets you high. But THC might be able to do more than that. Research suggests that it might also have the following properties:

• Anti-pain. Like CBD, THC could be used to treat pain, according to research. Dronabinol has been shown to reduce pain, which is another reason why it can be helpful for HIV/AIDS patients.
• THC might be able to improve sleep quality. A 2017 review of studies note that some evidence suggests it makes you sleep worse, while other studies suggest THC could treat insomnia.
• PTSD treatment. Since THC reduces the amount of time we spend dreaming, it might be able to help PTSD patients who struggle with nightmares.
• One side effect of the cannabis plant is the “munchies”- THC can make you hungry. Dronabinol, a synthetic version of THC, is an appetite-stimulant given to HIV/AIDS patients who have a low appetite.
• Anti-nausea. THC could reduce chemotherapy-induced nausea and vomiting. In fact, over 30 studies suggest that synthetic THC can treat CINV.

THC remains an interesting cannabinoid, and there’s a lot we still don’t know about it. It’s still being studied further by researchers. Future research will help us understand the effects of cannabis and THC better.

Cannabigerol (CBG)

CBG is fast gaining popularity, with some calling it “the new CBD”. CBG is the “mother cannabinoid” - every other cannabinoid comes from CBG. It’s also the most expensive cannabinoid to produce.

While the research on CBG is still in its infancy, research has identified quite a few potential benefits of CBG. For example, it may have the following properties:

• A promising 2015 study showed that CBG seemed to protect neurons in mice with Huntington’s disease. The study concluded that CBG should be tested for its potential to treat other neurodegenerative diseases, too.
• Anti-inflammatory. A murine study showed that CBG seemed to reduce the inflammation associated with inflammatory bowel disease.
• Anti-bacterial. Some research suggests that CBG might be able to kill methicillin-resistant Staphylococcus aureus (MRSA), which causes staph infections.
• Anti-cancer. A 2014 study showed that CBG slowed the growth of colon cancer cells in mice.
• Mood-boosting. Studies suggest that CBG increases the “bliss molecule,” anandamide, which improves your mood. It also might work as a GABA reuptake inhibitor, which can help reduce anxiety.

Not sure where to get CBG products? Check out our 5000mg CBG capsules, our CBG hemp flowers, and our CBG kief.

Cannabinol (CBN)

When THC is exposed to carbon dioxide for a long period of time, it becomes CBN. For this reason, more mature cannabis tends to turn into CBN. There are a number of potential benefits of CBN, although they are mostly conducted on rats and mice, and all need to be studied further.

These potential properties include:

• One lab study suggested that CBN could kill MRSA bacteria, which causes staph infections.
• Anti-inflammatory. A rodent study conducted in 2016 showed that CBN reduced inflammation in rats with arthritis.
• Appetite stimulant. A study suggested that CBN increases the appetite—it made rats eat more food, and eat for a longer period of time.
• Another study conducted on rodents found that CBN delayed the onset of ALS in rats.

Cannabichromene (CBC)

There are relatively few studies on CBC. However, the studies that are out there are quite promising. CBC might be able to treat:

• Pain and inflammation. As with most cannabinoids, CBC seems to reduce the pain and inflammation associated with osteoarthritis, according to a 2011 study. Another study showed that CBC and THC together reduce inflammation.
• A 2016 study suggests that CBC could treat acne.
• A 2010 study suggested that, together with THC, CBC might be able to treat depression.
• A 2006 study found that CBC is the second-most-potent cannabinoid at slowing the cancer cells, second to CBG. Unfortunately, this hasn’t been studied in humans.

CBC shows a number of potential benefits, but these all need to be studied further before we fully understand its effects on humans.

While these aren’t the only cannabinoids there are, they’re the most well-studied and possibly the most important. Future studies will probably uncover the importance of many other cannabinoids which could be harnessed to treat certain health conditions.

How to Benefit from the Entourage Effect and full spectrum CBD

One of the simplest ways to benefit from the entourage effect is to look for products that are “full-spectrum.” We have a range of full-spectrum items including but not limited to, full-spectrum CBD tinctures, and a broad-spectrum tincture option for those who don’t want to ingest THC.

Hemp flower is, by definition, full-spectrum. As it’s not processed and the form isn’t changed, we don’t remove any of the natural cannabinoids found in the bud. Our high-quality flowers allow you to make your own potent extracts and concentrates - and, of course, you can smoke them if you prefer.

Full-spectrum CBD doesn’t just come in the form of buds and tinctures. Our edibles and topical CBD, for example, also contain full-spectrum CBD. Experiment with different forms of CBD products until you find a product that you enjoy using.

Understanding the entourage effect can equip you with the knowledge you need to choose the best CBD products for your needs. Remember to speak to your doctor before using CBD to treat any particular ailment.

‍

The days of an outdated and frankly inaccurate cannabis classification system are finally over. The market has blurred the lines between quality and craft cannabis for far too long - leaving customers and cultivators with no real roadmap to identify the range and spectrum of the medicinal possibilities contained within cannabis and the unique entourage effects possible from the diversity that it offers.

Experts consider Cannabis Indica, Sativa, and Hybrid the three main subspecies - the issue is that people have used the THC potency of strains to determine superiority. Measuring potency and the effects with this method is a long-outdated classification system, especially when it does not provide accurate labels for customers and budtenders alike. The words “Indica” and “Sativa” were introduced in the 18th century to describe different species of cannabis, but modern research has led to more information that we will share throughout this article.

Historically, this is how cannabis has been defined;

Strains

Cannabis Sativa

Sativa is supposedly uplifting and cerebral, enhancing creativity and productivity. Indicas provide what has been called a “body high,” while Sativa’s deliver more of a “mind high.” Unfortunately, Sativa plants require longer to grow and yield less medicine (flowers) than Indica varieties. Sativa’s smell sweet, fruity, or spicy. This difference in the aroma results from terpenes, the molecules within the plant that are cousins to cannabinoids like THC and CBD. While these chemicals sometimes provide stunningly pungent odors, their greatest benefit to patients is their medicinal efficacy.

The problem with the general ‘idea’ of what a Sativa does, is that there is no accurate spectrum representing an understandable visual for growers and customers to understand easily.

Cannabis Indica

The typical example of Cannabis Indica is a more compact, thick-stemmed bush than its cousins, usually reaching a height of fewer than two meters. The foliage is generally a dark shade of green, some examples appearing to have almost blue or green-black leaves. These leaves are composed of short, wide blades.

Most Indicas are supposedly a rich source of the cannabinoids THC, CBD, and CBN. While Cannabis Sativa often produces a higher proportion of THC than its other cannabinoids, Cannabis Indica usually contains significant levels of all three. Indicas tend to have more body-centered effects than Sativas – enhancing physical sensations, which is not accurately measured either.

Cannabis Hybrids

Typically, a Hybrid is a cannabis plant with Indica and Sativa characteristics. Because cannabis has been cultivated for centuries, most modern strains are hybrid. Pure Sativas and pure Indicas are rare, so most cannabis you'll find these days is a hybrid.

Hybrid strains typically develop either Sativa-dominant, Indica-dominant, or evenly balanced phenotypes. Strain descriptions usually list it that way or display the split as a percentage. Remember that the terms Indica and Sativa strains are most useful for cultivators in determining growth characteristics like how tall plants will grow or how long their flowering cycle will be. Effects share no apparent connection with today's cannabis plants' physical structure, hence why the classification system is largely outdated.

So why is this a problem?

According to SC labs (SC Labs is a company that offers comprehensive solutions for cannabis and hemp testing) co-founder, Josh Wurzer;

“The problem is that there is little standardization when it comes to defining and determining terpenes”

Measuring the superiority of cannabis is confusing, and frankly, the classification system is completely outdated. It no longer only comes down to the strain. The days of just searching out the highest THC totals are rapidly receding. Research has proven that terpenes are at the base of the entourage effect, where previously, it has been considered ‘minor’ information. Cannabis growers and breeders have been assigning labels to cultivars primarily based on aroma profiles and purported effects rather than genetic ancestry or overall chemical similarity. Cultivators, processors, retailers, and consumers could benefit from greater standardization when evaluating product quality and distinguishing label claims.

Because cannabis is a widely used substance increasingly being legalized for medicinal and recreational use, Cannabis’s genetic and chemical variation must be accurately quantified and communicated. Using strain labels like Sativa and Indica are used to describe a cultivar’s morphology, aromas and/or psychoactive effects. However, whether these labels capture meaningful information about Cannabis's genetic and chemical variation is incredibly unclear. This leaves room for inaccuracy and uncertainty in a world growing in popularity faster than any other industry.

In this study, the inaccuracy of reporting is clear;

“This is consistent with previous studies indicating that cultivar names were not reliable indicators of a sample’s genetic or chemical identity”

The study shows that the genetic structure of cannabis explained only 37% of the variance in labeling, meaning that Sativa–Indica labels do not accurately reflect genetic relatedness. When the study looked at the correlation of Sativa and Indica terpenes and cannabinoids, Sativa content was positively correlated with the concentrations of bergamotene and farnesene. While on the other hand, there were significant positive correlations between Indica labeling and three sesquiterpenes: guaiol, γ-eudesmol, and β-eudesmol. This shows that it goes far beyond mere classification, and it really comes down to far more than simple labels.

The contrasting aromas that have been associated with Sativa (that is, sweet) and Indica (that is, earthy) were key discriminators in a sensory evaluation of Cannabis cultivars and mediated customers’ perceptions of potency and quality.

What is the solution?

Simple; replace the three vague classes with six elaborate and detailed classifications instead. On February 16th, – SC Laboratories, Inc., (SC Labs) announced that it has licensed Napro Research LLC’s proprietary data visualization tool PhytoFacts®. Clients testing cannabis through the lab will now have access to this game-changing reporting format and algorithm that provides a visual profile of each strain’s chemical makeup. This new report format is intuitive and helps budtenders and consumers identify the right strain for their desired effect. As mentioned above, the terpene profile proves to be far more important than the breed of cannabis, which means that companies like SC Labs are putting an end to the days of simply seeking out the highest THC percentage. Science has converged to finally prove that terpenes are at the root of the entourage effect that consumers are seeking.

Always looking to level their playing field and eliminate as much bias as possible, SC labs' owners partnered with the event organizers of Emerald Cup and NAPRO research to help reframe the conversation regarding what defines “quality” in cannabis. The Emerald Cup is widely believed to be the World Series of Cannabis competitions as it is rooted in Humboldt County. The partnership is intended to help revolutionize the collective understanding of the true role of terpene content.

The new classification system focuses on sorting flower entries by primary terpene content, leveraging a combined decade of research into Cannabis phytochemistry between  PhytoFacts® coupled with a powerful database of over 250,000 terpene tests and aggregated by SC Labs, going back to their launch of terpene testing on Cannabis in 2013 as you can see below.

What are the new classes?

‘Jacks + Haze’ Class

• Mostly ‘Sativa’-leaning varietals
• Tasting notes – Fruity, Pinesol, Haze
• Effects – Energizing, Cerebral, Artistically Inspiring
• Common Cultivars – Classic Trainwreck, Jack Herer, Durban Poison, Super Lemon Haze
• Terpenes Profile: Terpinolene, Caryophyllene, Myrcene

‘Sweets + Dreams’ Class

• Mostly ‘Indica’-leaning varietals
• Tasting Notes – Fruity, Sweet, Woody, Hoppy, Herbaceous
• Effects – Relaxation, Couch Lock, Analgesic
• Common Cultivars – Blue Dream, Tangie, Forbidden Fruit, Grandaddy Purple, Purple Urkel, Grape Ape, Cherry AK, God’s Gift, Purple Punch
• Terpenes Profile: Myrcene, Pinene, Caryophyllene

‘Tropical + Floral’ Class

• Mostly ‘Indica’-leaning varietals
• Tasting notes – Sweet, Floral, Tropical Fruit
• Effects – Calming, Soothing, Relaxing
• Common Cultivars – Super Skunk, Hawaiian, In the Pines, Dream Queen
• Terpenes Profile: Ocimene, Myrcene

‘OGs + Gas’ Class

• True ‘Hybrid’ varietals
• Tasting Notes – Gas, Fuel, Sweet, Citrus, and Pepper
• Effect – Uplifting, Stimulating, Analgesic, Relaxation
• Common Cultivars – Classic OG Kush, Chemdog, Sour Diesel, Gorilla Glue
• Terpenes Profile: Any combination or shifting codominance of Caryophyllene, Limonene, Myrcene

‘Exotics’ (Rare Terpene Combinations) Class

• True ‘Hybrid’ varietals
• Tasting notes – varied based on chemistry of entry
• Effect – varied based on chemistry of entry
• Common Cultivars – rarest terpene profiles entered into the Emerald Cup Competition

‘Desserts’ Class

• True ‘Hybrid’ varietals
• Tasting Notes – Deserts, Doughs, Citrusy & Spicy
• Effects – Stimulating, Racy, Uplifting, Comforting
• Common Cultivars – Classic Bubba Kush, GSC, Gelatos, Cakes
• Any shift in codominance of Caryophyllene & Limonene

How We’re Using The New System

Because of the reliability and shift in the right direction, Black Tie CBD has made use of the latest testing for our ‘ChemDawg’ strain, as you can see below;

As you can see from the report produced by PhytoFacts®, there’s immense detail about the aroma & flavor, identifying the spectrum of profiles in depth. The particular aroma and tastes lean far more towards earthy with some sweet and fruity profiles. Similarly, the entourage effect is highlighted, giving the budtender or end-user a clear idea of its effects. The relaxation and comfort of the strain are highlighted, with lower energy levels. The report is easy to understand and interpret, and above all the classification is distinct without being confusing.

This goes to show how important terpenes really are, and how the entourage effect varies depending on multiple facets which are not usually shown - including highlights of b-Caryophyllene (3.943 mg/g), Myrcene (3.767 mg/g), Terpinolene (2.605 mg/g). The relevance of highlighting terpenes matters significantly because terpenes have also been identified as a new frontier in cannabis medicine. Until recently, the spotlight has been focused almost exclusively on the therapeutic qualities of cannabinoids, such as THC and CBD, but as our understanding of terpenes grows more sophisticated, it’s becoming apparent that these aromatic compounds are medicinal powerhouses too.

β-Caryophyllene: β-Caryophyllene is generally the most common sesquiterpene in cannabis, and the most abundantly produced terpene in Nature. Over the last decade, it has gained scientific attention after discovering that it can directly activate cannabinoids receptors. Basically, the β-Caryophyllene terpene acts as a cannabinoid.

This is the terpene that contributes to the ever-so-slight spicy flavor, but mainly to the earthy profiles as well as the relaxation quality of this strain.

Myrcene: Myrcene is the most abundant terpene in modern commercial cannabis. Myrcene has many therapeutic benefits. Like other terpenes, myrcene is believed to have potential anti-inflammatory, potential anti-tumor, sleep-supportive, and other health benefits.

Myrcene characteristically gives our cannabis strain a mildly sweet flavor profile and provides scent notes that are spicy, earthy and muskiness - and also contributes towards that relaxing and calm effect that was mentioned.

Terpinolene: Terpinolene, a terpene dominant in about one in ten cannabis strains, is recognized for its woody smell combined with floral citrus notes. In addition to its fresh aroma, terpinolene is known for its antifungal and antibacterial properties. Terpinolene is considered more multidimensional in comparison to other cannabis terpenes.

These combined effects and profiles of terpinolene are why there are more fruity aromas and comforting effects. The combination of all three highlighted terpenes should indicate the importance of a more accurate and science-backed classification system to ensure that all effects, aromas and profiles are accounted for.

Without having to handle the substance, users and budtenders can now have a true discourse about the desired flavor, fragrance, and potential effects of cannabis. Consumers may now finally buy cannabis online with ease thanks to the new classification system and PhytoFact® information.

‍

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin.

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries.

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV.

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids.

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain.

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity.

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal?

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV.

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations.

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.

‍

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin. 

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries. 

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV. 

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids. 

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain. 

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity. 

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal? 

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV. 

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations. 

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin. 

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries. 

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV. 

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids. 

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain. 

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity. 

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal? 

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV. 

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations. 

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.